Payment overview · 2025
General Payments
$862.16
43 reported records · 16 companies
Healthcare provider profile · identity verified
Amy V Gorczynski, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WHITESBORO, NY · NPI 1225022437
Verified facts
What the public records show
CMS Open Payments records show Amy V Gorczynski, M.D. received $862.16 in general payments during 2025 across 43 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.00 | 23.6% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $127.16 | 14.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.54 | 10.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.95 | 7.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $55.30 | 6.4% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $47.43 | 5.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.04 | 5.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.68 | 4.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.51 | 4.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.47 | 4.2% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.92 | 2.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.42 | 2.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.82 | 2.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.62 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.54 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.76 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $862.16 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $144.08 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $130.23 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $129.57 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $86.81 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $76.92 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.95 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.95 | 4 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $47.43 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.04 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.51 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.47 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 258 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 256 | 88 |
| Losartan Potassium | Losartan Potassium | 208 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 174 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 24 |
| Alprazolam | Alprazolam | 168 | 31 |
| Lorazepam | Lorazepam | 163 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 46 |
| Omeprazole | Omeprazole | 148 | 55 |
| Ezetimibe | Ezetimibe | 118 | 38 |
| Sertraline Hcl | Sertraline Hcl | 112 | 39 |
| Tramadol Hcl | Tramadol Hcl | 110 | 32 |
| Furosemide | Furosemide | 108 | 41 |
| Lisinopril | Lisinopril | 108 | 32 |
| Potassium Chloride | Potassium Chloride | 105 | 31 |
| Metformin Hcl | Metformin Hcl | 104 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 17 |
| Glimepiride | Glimepiride | 98 | 27 |
| Prednisone | Prednisone | 92 | 49 |
| Eliquis | Apixaban | 90 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 35 |
| Gabapentin | Gabapentin | 88 | 31 |
| Pregabalin | Pregabalin | 84 | 17 |
| Ozempic | Semaglutide | 82 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 69 | 21 |
| Bupropion Xl | Bupropion Hcl | 68 | 22 |
| Meloxicam | Meloxicam | 67 | 25 |
| Simvastatin | Simvastatin | 66 | 19 |
| Azithromycin | Azithromycin | 65 | 53 |
| Xarelto | Rivaroxaban | 64 | 18 |
| Torsemide | Torsemide | 62 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 50 |
| Montelukast Sodium | Montelukast Sodium | 60 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 22 |
| Ramipril | Ramipril | 54 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 19 |
| Carvedilol | Carvedilol | 49 | 17 |
| Celecoxib | Celecoxib | 49 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 18 |
| Donepezil Hcl | Donepezil Hcl | 48 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 14 |
| Allopurinol | Allopurinol | 46 | 15 |
| Vilazodone Hcl | Vilazodone Hcl | 46 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 11 |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 11 |
| Jardiance | Empagliflozin | 33 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 32 | 11 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Diazepam | Diazepam | 22 | 11 |
| Famotidine | Famotidine | 22 | 11 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Telmisartan | Telmisartan | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lorazepam Intensol | Lorazepam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $862.16 · 43 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INJECTAFER, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error